Company Overview
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026. OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.
Recent Developments
- Dec 2025 Revenue of $2.91M (-17.7% YoY); net profit $-18.01M.
- Trailing 12 Months Year-on-year growth — revenue -72.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -72.20% |
Stock Price Performance
| 1 Year: | -64.17% |
| 6 Months: | -59.96% |
| 3 Months: | -50.12% |
| 1 Month: | -54.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 80.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OSRH OSR Health, Inc. PHARMA | 0.20 | -0.67 | $7.02M | 0.00% | -11.90% | -11.29% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 823.00K | 761.27K | 1.14M | 627.75K | 381.27K | 484.06K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 592.59K | 1.10M | 366.01K | 251.56K | 323.78K |
| Gross Profit | - | - | - | - | - | - | 239.80K | 232.32K | 179.09K | 168.69K | 32.78K | 261.73K | 129.70K | 160.28K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 3.09M | 5.26M | 4.07M | 6.52M | 3.83M |
| Operating Income | - | - | - | - | - | - | -3.30M | -3.21M | -3.57M | -2.92M | -5.23M | -3.80M | -6.39M | -3.67M |
| EBITDA | - | - | - | - | - | - | - | - | - | -9.10M | -2.84M | -2.06M | -5.08M | -1.46M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 16.40K | 36.93K | 43.87K | 409.00K | 31.22K |
| Pretax Income | - | - | - | - | - | - | - | - | - | -11.39M | -5.23M | -4.49M | -7.78M | -3.92M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 0 | 0 | -1.29M | -534.87K | -452.31K |
| Net Income | -126 | -988 | -20.02K | 110.31K | 301.46K | 78.18K | -60.43K | -97.30K | -230.96K | -11.39M | 331.41K | -2.13M | -4.82M | -2.93M |
| Diluted EPS | - | 0.00 | -0.01 | 0.02 | 0.03 | 0.01 | -0.01 | -0.02 | -0.06 | -1.04 | 0.02 | -0.10 | - | -0.09 |
| R&D Expense | - | - | - | - | - | - | 46.72K | - | - | 90.15K | - | - | - | 113.15K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 3.53M | 2.91M |
| Cost of Revenue | - | 0 | 2.53M | 2.72M | 2.31M |
| Gross Profit | - | 0 | 921.41K | 811.24K | 592.90K |
| Operating Expenses | - | 621.32K | 1.83M | 12.50M | 18.93M |
| Operating Income | -3.31K | -621.32K | -1.83M | -11.69M | -18.34M |
| EBITDA | - | 1.10M | 944.59K | -2.15M | -19.08M |
| Interest Expense | - | 14.22K | 0 | 51.34K | 506.20K |
| Pretax Income | - | 1.06M | 944.59K | -11.89M | -28.89M |
| Tax Provision | - | 0 | 540.81K | -1.56M | -1.83M |
| Net Income | -3.31K | 1.06M | 403.78K | -10.33M | -18.01M |
| Diluted EPS | - | 0.49 | 0.19 | -0.54 | -0.92 |
| R&D Expense | - | - | - | 161.16K | 318.45K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 705.09K | 120.76M | 36.63M | 175.24M | 171.24M |
| Current Assets | - | - | 4.42M | 22.63K | 2.33M | 2.82M |
| Cash & Equivalents | - | 4.76K | 2.82M | 15.42K | 341.54K | 1.70M |
| Inventory | - | - | 1.08M | 1.80B | 922.11K | 196.43K |
| Receivables | - | - | 372.40K | 1.48B | 904.46K | 319.30K |
| Total Liabilities | - | 707.21K | 21.66M | 4.11M | 32.03M | 44.20M |
| Current Liabilities | - | 707.21K | 5.86M | 2.04M | 3.46M | 17.17M |
| Long Term Debt | - | - | 126.69K | 460.00M | 497.62K | - |
| Total Debt | - | - | 1.56M | 1.17B | 2.38M | 4.40M |
| Total Equity | 1.19K | -2.12K | 99.10M | 32.52M | 143.21M | 77.64M |
| Shares Outstanding | - | - | 19.28M | 19.28M | 19.28M | 26.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -461 | -516.31K | -818.77K | -1.85M | -4.33M |
| Investing Cash Flow | - | -1.71M | -33.83M | 503.61K | -2.64M |
| Financing Cash Flow | -57.44K | 4.72M | 34.54M | 1.18M | 8.37M |
| Capital Expenditure | - | -77.39K | -16.32K | - | -176.38K |
| Free Cash Flow | - | -593.70K | -818.77K | -1.85M | -4.50M |
| Net Change in Cash | - | 2.49M | -109.08K | -161.53K | 1.40M |
| Share Buybacks | - | - | 36.00M | 36.23M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 23.0% | 20.4% |
| Operating Margin % | - | - | - | -331.2% | -631.0% |
| Net Margin % | - | - | - | -292.6% | -619.8% |
| ROE % | 156.0% | 1.1% | 1.2% | -7.2% | -23.2% |
| ROCE % | 156.0% | -0.5% | -5.3% | -6.8% | -11.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Fiduciary Trust Co | 0.42% | 148.27K | $32.60K |
| 2 | Citadel Advisors Llc | 0.36% | 127.81K | $28.11K |
| 3 | Jane Street Group, LLC | 0.36% | 127.19K | $27.97K |
| 4 | Geode Capital Management, LLC | 0.29% | 100.46K | $22.09K |
| 5 | Two Sigma Securities, LLC | 0.13% | 46.54K | $10.23K |
| 6 | Vanguard Capital Management LLC | 0.11% | 37.37K | $8.22K |
| 7 | Xtx Topco Ltd | 0.09% | 32.38K | $7.12K |
| 8 | Susquehanna International Group, LLP | 0.05% | 18.28K | $4.02K |
| 9 | Northern Trust Corporation | 0.03% | 10.91K | $2.40K |
| 10 | Mint Tower Capital Management B.V. | 0.02% | 7.50K | $1.65K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OSRH
OSR Health, Inc. Actuals & Estimates (OTC:OSRH) - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxQU1NGcFlWT0pqc1hYaS15M2RLNnhSdVpFQVVSSHpLMTJBR2lER3B3d1BNbmlPSjF5SUh3bDU2T2dUaURvNVVtbTFwMUFmX25xdFk3eGFaRFhCemtOX1oyYTA1eXZ2THd3TFk3UGlHWWV3X2RfR0Ytc1BXZ1gxalRaXzlB?oc=5" target=…
Why OSR Health (OSRH) Stock Is Up Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxNaVhTNXp1eGc3Nm9Ed1h2aWVuNW1LZldaU2NnYWk5MFhqREx5V1dSRWljZ1BWNUZ4SkJrc3NoY1ZmcEItdTZ0X2ZhZlBVRW91bEV3Vl91XzdUS1ZxTWloQm02QmhJeGdRUkpibnJRRC1kckdXeFY1S0Q3U2FzU0QyLVNR?oc=5" target=…
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPWkRzaEhMc1R3V2p0UV9mZzM5Nk9qWEpxYWR5MS0zd25VZTJtVEx2UUNxLUdxWTAwWUNDUGQ5WXBhd2s3Q1FaWWN3UmF1STRUaldQSFQ2c3dnWnBzUE1EanhMOFY1SWduLWg5dnBJY3pOYXNBS1k2TmF6Zm0zaWtaN1dTZm1qZ0x1b3N1bU…
Why Did OSRH Stock Jump 20% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOcDZCZmRFRlBXTkI0MWI3WjVLbjZJeU5RMnM1MVk0MmJpalhmYVhFbEw5MG5xNERaWUxVdDkwOGJzaDRfTTBWVVFmWlE0N2Z1azZBZFB5RGJEdG1JSm1MMm02Rm1VZFc5U3pDeE5JcEc4YlBlOTRiVWtkMWNMaFliekhkcjhOX3Q1ZG5MRH…
OSR Health, Inc. - Common Stock (Nasdaq:OSRH) Stock Quote - FinancialContent
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE1aMHpDbF9aLXU4d3VxZzgwX21wbC1QUEZWemlLeXhZOF9FZnpyTVFvWV9pQmhsaHZzOTFnMFlvYU5EM2JGSXdxYkpfTFAtVU9fcHBxOG9CY0JUb0hSLVhpUDhoWE5RWWtobXNESTBaZGtkN2Zp?oc=5" target="_blank">OSR Health,…
Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc. - Morningstar
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPRnQzdDdEVlZmT0NleWNieHVzUW1FMld1dlU4c01XcnNrYTQ3V01adXdPQXpYbGV3dFNWWGQ5YU5iWHFNQUVoNGtHZVJPLUtyeDA0QU5hRzhzVTBlTDNUbHpkQnNYeWF1bDBtZXRFNjBYNmlrQUFlbVdLZDhNVE9OWFQ1MW1RbUtxMWdqWF…
OSRH — Frequently Asked Questions
What is the current share price of OSR Health, Inc. (OSRH)?
As of 2026-09-19 21:16 PDT, OSR Health, Inc. (OSRH) trades at $0.20 on OTC Markets OTCPK. Its 52-week range is $0.12 to $1.01.
What is the market capitalisation of OSRH?
OSR Health, Inc. (OSRH) has a market capitalisation of $7.02M on OTC Markets OTCPK.
What is the P/E ratio of OSRH?
OSRH trades at a trailing price-to-earnings (P/E) ratio of -0.67. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.07.
What is the return on equity (ROE) of OSRH?
OSRH has a return on equity (ROE) of -11.29%. Its return on capital employed (ROCE) is -11.90%.
Is OSRH a good stock to buy?
This page provides a data-driven analysis of OSR Health, Inc. (OSRH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.